Botulinum toxin type A versus anticholinergics for cervical dystonia

Rodrigues, Filipe B; Duarte, Gonçalo S; Castelão, Mafalda; Marques, Raquel; Ferreira, Joaquim J.; Sampaio, Cristina; Moore, Austen P; Costa, João

doi:10.1002/14651858.cd004312.pub2

Cited by 21 publications

(9 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Importantly, the treatment of motor problems should be multidisciplinary, foremost consisting of intensive support from a rehabilitation physician and allied health care professionals, only sometimes combined with drug therapy. [27][28][29] Oral drug therapy with anticholinergic drugs (e.g. In general, treatment of ataxia is difficult owing to the lack of effective drugs.…”

Section: Neurology Motor Dysfunction Backgroundmentioning

confidence: 99%

Ataxia‐telangiectasia: recommendations for multidisciplinary treatment

Haaxma

Flier

et al. 2017

Develop Med Child Neuro

View full text Add to dashboard Cite

Ataxia-telangiectasia is a rare, neurodegenerative, and multisystem disease, characterized by cerebellar ataxia, oculocutaneous telangiectasia, immunodeficiency, progressive respiratory failure, and an increased risk of malignancies. It demands specialized care tailored to the individual patient's needs. Besides the classic ataxia-telangiectasia phenotype, a variant phenotype exists with partly overlapping but some distinctive disease characteristics. This guideline summarizes frequently encountered medical problems in the disease course of patients with classic and variant ataxia-telangiectasia, in the domains of neurology, immunology and infectious diseases, pulmonology, anaesthetic and perioperative risk, oncology, endocrinology, and nutrition. Furthermore, it provides a practical guide with evidence- and expert-based recommendations for the follow-up and treatment of all these different clinical topics.

show abstract

Section: Neurology Motor Dysfunction Backgroundmentioning

confidence: 99%

Ataxia‐telangiectasia: recommendations for multidisciplinary treatment

Haaxma

Flier

et al. 2017

Develop Med Child Neuro

View full text Add to dashboard Cite

show abstract

“…Most CD patients who receive medications such as trihexyphenidyl, carbamazepine, clonazepam, and baclofen report sustained symptoms and suffer from unpleasant side effects 2,3,5,6. Interestingly, intramuscular injections of botulinum toxin A offer higher efficacy and fewer side effects than other treatments 5–14. Botulinum toxin A is a highly potent neurotoxin that is used to treat various diseases including hemifacial spasm, spasticity, dystonia, and achalasia.…”

Section: Introductionmentioning

confidence: 99%

“…Botulinum toxin A is a highly potent neurotoxin that is used to treat various diseases including hemifacial spasm, spasticity, dystonia, and achalasia. Treatment by botulinum toxin A is shown to improve the quality of life of CD patients 3,5–16. Botulinum toxin A is approved by the Food and Drug Administration of the United States for CD treatment and is recommended by most guidelines as a first-line treatment worldwide.…”

Section: Introductionmentioning

confidence: 99%

Quality of life in cervical dystonia after treatment with botulinum toxin A: a 24-week prospective study

Kongsaengdao¹,

Maneeton²,

Maneeton³

2017

NDT

View full text Add to dashboard Cite

ObjectiveThis study aimed to identify possible improvements in disease-specific health-related quality of life (HRQoL) after multiple injections of botulinum toxin A over 24 weeks in Thai cervical dystonia (CD) patients.Materials and methodsA 24-week prospective study comparing HRQoL of Thai CD patients before and after multiple injections of botulinum toxin A at 3-month intervals was performed. Disease-specific HRQoL was assessed by using the Cervical Dystonia Impact Profile-58 questionnaire (CDIP-58) and the Craniocervical Dystonia Questionnaire-24 (CDQ-24). General HRQoL was assessed by using the Medical Outcomes’ 36-Item Short Form Health Survey (SF-36) and the EuroQoL 5-dimension questionnaire (EQ-5D). All the assessments were performed before and after the 24-week treatment period.ResultsA total of 20 CD patients were enrolled in this study from April to December 2011. CDIP-58 and CDQ-24 scores, which assess disease-specific HRQoL, showed a significant improvement after 24 weeks of treatment by botulinum toxin A (P<0.001). However, EQ-5D and SF-36 scores, which assess general HRQoL, showed no significant improvement after the treatment (P>0.05).ConclusionCD patients’ disease-specific HRQoL improved after being treated with multiple botulinum toxin A injections. However, general HRQoL was not improved.

show abstract

“…Furthermore, the available evidence suggests that BoNT-A injections provide more objective and subjective benefits than an anticholinergic drug (i.e. trihexyphenidyl) to patients with cervical dystonia (34).…”

Section: Evidence-based Medicinementioning

confidence: 99%

Dystonia, Spasticity and Botulinum Toxin Therapy: Rationale, Evidences and Clinical Context

Rosales¹

2012

Dystonia - The Many Facets

View full text Add to dashboard Cite

Botulinum toxin type A versus anticholinergics for cervical dystonia

Cited by 21 publications

References 13 publications

Ataxia‐telangiectasia: recommendations for multidisciplinary treatment

Ataxia‐telangiectasia: recommendations for multidisciplinary treatment

Quality of life in cervical dystonia after treatment with botulinum toxin A: a 24-week prospective study

Dystonia, Spasticity and Botulinum Toxin Therapy: Rationale, Evidences and Clinical Context

Contact Info

Product

Resources

About